Natalizumab Treatment of Relapsing Remitting Multiple Sclerosis Has No Long-Term Effects on the Proportion of Circulating Regulatory T Cells. (2023)

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1007/s40120-023-00539-9

PubMed Identifier: 37715885

Publication URI: http://europepmc.org/abstract/MED/37715885

Type: Journal Article/Review

Volume: 12

Parent Publication: Neurology and therapy

Issue: 6

ISSN: 2193-6536